1993
|
Sign up to set email alerts
Terazosin in the treatment of benign prostatic hyperplasia. Terazosin Benign Prostatic Hyperplasia Study Group
Search citation statements
Order By: Relevance
Paper Sections
Select...
68
3
2
2
Citation Types
2
33
0
3
Year Published
Range
1994
19942024
2024Publication Types
Select...
67
7
1
Relationship
0
75
Authors
Journals
Cited by 75 publications
(38 citation statements)
References 0 publications
2
33
0
3
Order By: Relevance
Smart CitationsHow the paper below cites the one you are viewing
“…In contrast, the blood pressure effects of tamsulosin were similar to those of placebo in controlled studies, both in normotensive and in hypertensive patients [10]. The blood pressure reductions seen with tamsulosin for patients without concomitant disease in the present study were similar to those previously reported for tamsulosin or placebo in the BPO population [10, 19, 21]. In the multiple regression analysis of the present study, the blood pressure-lowering of tamsulosin was almost completely explained by baseline blood pressure values.…”
Section: Discussion
supporting
confidence: 88%
Smart CitationsHow the paper below cites the one you are viewing
“…In contrast, the blood pressure effects of tamsulosin were similar to those of placebo in controlled studies, both in normotensive and in hypertensive patients [10]. The blood pressure reductions seen with tamsulosin for patients without concomitant disease in the present study were similar to those previously reported for tamsulosin or placebo in the BPO population [10, 19, 21]. In the multiple regression analysis of the present study, the blood pressure-lowering of tamsulosin was almost completely explained by baseline blood pressure values.…”
Section: Discussion
supporting
confidence: 88%
Smart CitationsHow the paper below cites the one you are viewing
“…assuming tachyphylaxis to develop for such reactions) [18]. This approach, which underlies the regimen for terazosin as investigated in the present study, is acclaimed to be relatively safe [23, 41, 42]. The present study confirms that this approach avoids excessive ambulatory blood pressure reduction whilst failing to prevent nocturial orthostatic hypotension; indeed it may aggravate it.…”
Section: Discussion
supporting
confidence: 70%
Smart CitationsHow the paper below cites the one you are viewing
“…In the study by Brawer et al [10], the investigators' assessment score of overall outcome improved by 14% from baseline for men assigned to terazosin, and by 0% for placebo ( P 0.05). Roehrborn et al [18] reported that more men treated with terazosin had a better quality of life score (33% vs 16% of men taking placebo, P < 0.001).…”
Section: Results
mentioning
confidence: 99%
“…The percentage changes in symptoms were −31% to −69% for terazosin (improvement) and −10% to −58% for placebo. The pooled mean percentage improvement for the placebo‐controlled trials using the Boyarsky symptom score was 37% for terazosin and 15% for placebo [10,13,15,17]. In the two withdrawal studies, symptom scores worsened by 15–25% for men remaining on terazosin, and by 41–63% for men withdrawn from terazosin and assigned to placebo [11,14].…”
Section: Results
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…In contrast, the blood pressure effects of tamsulosin were similar to those of placebo in controlled studies, both in normotensive and in hypertensive patients [10]. The blood pressure reductions seen with tamsulosin for patients without concomitant disease in the present study were similar to those previously reported for tamsulosin or placebo in the BPO population [10, 19, 21]. In the multiple regression analysis of the present study, the blood pressure-lowering of tamsulosin was almost completely explained by baseline blood pressure values.…”
Section: Discussion
supporting
confidence: 88%
Smart CitationsHow the paper below cites the one you are viewing
“…assuming tachyphylaxis to develop for such reactions) [18]. This approach, which underlies the regimen for terazosin as investigated in the present study, is acclaimed to be relatively safe [23, 41, 42]. The present study confirms that this approach avoids excessive ambulatory blood pressure reduction whilst failing to prevent nocturial orthostatic hypotension; indeed it may aggravate it.…”
Section: Discussion
supporting
confidence: 70%
Smart CitationsHow the paper below cites the one you are viewing
“…In the study by Brawer et al [10], the investigators' assessment score of overall outcome improved by 14% from baseline for men assigned to terazosin, and by 0% for placebo ( P 0.05). Roehrborn et al [18] reported that more men treated with terazosin had a better quality of life score (33% vs 16% of men taking placebo, P < 0.001).…”
Section: Results
mentioning
confidence: 99%
“…The percentage changes in symptoms were −31% to −69% for terazosin (improvement) and −10% to −58% for placebo. The pooled mean percentage improvement for the placebo‐controlled trials using the Boyarsky symptom score was 37% for terazosin and 15% for placebo [10,13,15,17]. In the two withdrawal studies, symptom scores worsened by 15–25% for men remaining on terazosin, and by 41–63% for men withdrawn from terazosin and assigned to placebo [11,14].…”
Section: Results
mentioning
confidence: 99%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…In contrast, the blood pressure effects of tamsulosin were similar to those of placebo in controlled studies, both in normotensive and in hypertensive patients [10]. The blood pressure reductions seen with tamsulosin for patients without concomitant disease in the present study were similar to those previously reported for tamsulosin or placebo in the BPO population [10, 19, 21]. In the multiple regression analysis of the present study, the blood pressure-lowering of tamsulosin was almost completely explained by baseline blood pressure values.…”
Section: Discussion
supporting
confidence: 88%
Smart CitationsHow the paper below cites the one you are viewing
“…assuming tachyphylaxis to develop for such reactions) [18]. This approach, which underlies the regimen for terazosin as investigated in the present study, is acclaimed to be relatively safe [23, 41, 42]. The present study confirms that this approach avoids excessive ambulatory blood pressure reduction whilst failing to prevent nocturial orthostatic hypotension; indeed it may aggravate it.…”
Section: Discussion
supporting
confidence: 70%
Smart CitationsHow the paper below cites the one you are viewing
“…In the study by Brawer et al [10], the investigators' assessment score of overall outcome improved by 14% from baseline for men assigned to terazosin, and by 0% for placebo ( P 0.05). Roehrborn et al [18] reported that more men treated with terazosin had a better quality of life score (33% vs 16% of men taking placebo, P < 0.001).…”
Section: Results
mentioning
confidence: 99%
“…The percentage changes in symptoms were −31% to −69% for terazosin (improvement) and −10% to −58% for placebo. The pooled mean percentage improvement for the placebo‐controlled trials using the Boyarsky symptom score was 37% for terazosin and 15% for placebo [10,13,15,17]. In the two withdrawal studies, symptom scores worsened by 15–25% for men remaining on terazosin, and by 41–63% for men withdrawn from terazosin and assigned to placebo [11,14].…”
Section: Results
mentioning
confidence: 99%
Abstract